First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.
Jesper van BreeschotenMichel W J M WoutersDoranne L HilariusJohn B HaanenChristian U BlankMaureen J B AartsFranchette W P J van den BerkmortelJan-Willem B de GrootGeke A P HospersEllen KapiteijnDjura PiersmaRoos S van RijnKarijn P M SuijkerbuijkWilleke A M BlokxBert-Jan J Ten TijeAstrid A M van der VeldtArt VreugdenhilMarye J Boers-SonderenAlfonsus J M van den EertweghPublished in: British journal of cancer (2021)
Our data suggest that in the matched BRAFV600-mutant advanced melanoma patients, anti-PD-1 monotherapy is the preferred first-line treatment in patients with relatively favourable patient and tumour characteristics.